Cellular Health Screening Market Share Analysis Report, 2024-2033
The global cellular health screening market size was exhibited at USD 2.80 billion in 2023 and is projected to hit around USD 6.88 billion by 2033, growing at a CAGR of 9.4% during the forecast period of 2024 to 2033.
Key Takeaways:
Cellular Health Screening Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 2.80 Billion |
| Market Size by 2033 | USD 6.88 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 9.4% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Test Type, Sample Type, Collection Site, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Life Length, SpectraCell Laboratories, Inc., RepeatDx, Cell Science Systems, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, OPKO Health, Inc., Genova Diagnostics (GDX), Immundiagnostik AG, DNA Labs India. |
Over the projected period, the importance of precision medicine is expected to increase, along with the requirement to analyze biomarkers for aging and cellular health in general. In addition, cellular health screening plays a crucial role in monitoring the body’s reaction to treatment regimens, which is anticipated to contribute to the growth of the market. Companies involved in delivering cellular health screening goods and services noticed a reduction in their sales and base testing volume as a result of the COVID-19 pandemic.
In addition to the pandemic-related mandates by the government, the transportation restrictions and limitations on the import and export of raw materials and goods disrupted the supply chain. Owing to the decrease in demand as a result of supply chain disruption, many businesses have broadened their product lines to include COVID-19 molecular and antibody testing, which can equally counterbalance the decline in base testing volume.
The use of home diagnostic tests is significantly rising globally. The growing number of campaigns to educate the public about the signs of chronic diseases and how to prevent them in order to contain disease epidemics are expected to fuel growth. As a result, there is a significant demand for cellular health screening kits and services due to greater patient awareness. Additionally, the use of these devices helps to optimize prompt treatment decisions, increases the effectiveness of care given, and dramatically lowers diagnosis costs, especially in resource-constrained countries with inadequate laboratory facilities.
Numerous studies have shown a connection between malignancies and telomere length. Telomere shortening as a tumor suppressor turns out to be a significant factor in cancer that has progressed more severely. Although it has been demonstrated that a range of variables, including infections, inflammation, and stress, affect the length of telomeres and inflammation, in particular, causes oxidative stress, which, in turn, causes telomere erosion. According to research, telomere maintenance plays a significant role in how aging and related disorders are affected by environmental, lifestyle, and genetic factors. As a result, it is crucial to know how quickly telomeres change in order to understand biological aging and hereditary illnesses. Furthermore, telomere length loss has been linked to pathologies associated with aging, including cancer, cardiovascular illnesses, and weakened immune systems. The need for cellular health screening is projected to grow over the years with the rising incidence of chronic diseases, which further drives the market.
Growing awareness campaigns by numerous organizations throughout the world have played a significant role in increasing the demand for testing-based preventive healthcare products and services. One of the key factors anticipated to drive the market during the forecast period is collaborative efforts by organizations such as the CDC, the U.S. Preventive Services Task Force (USPSTF), the National Cervical Cancer Coalition, and the WHO.
In addition, major industry companies are launching campaigns to raise awareness about cervical and vaginal cancer screening to prevent mortality. For instance, as per the article published by theguardian.com, in February 2023, an awareness campaign has been launched in England to increase life-saving screening. This campaign was launched by the Department of Health and Social Care.
Test Type Insights
The single test panels segment held the largest share of 79.08% in 2023. Among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals, the telomere single test panel is expected to grow at the fastest rate over the forecast period. This can be attributed to various research studies showing the correlation of telomere length on multiple molecular and cellular functions. Moreover, the launch of new testing devices for the detection of telomere length further contributes to the growth. For instance, in September 2021, Genomic Vision launched TeloSizer to boost the use of telomere for biomarker discovery via its precise and quantitative detection.
The multi-test panels segment is estimated to witness the fastest growth during the forecast period. The utilization of these panels for screening multiple biomarkers during a single run has resulted in many advantages such as diagnostic competence, precision, and reduced costs in health care settings. These reasons are anticipated to increase the inclination toward multi-test panels rather than single-use panels in the future.
Sample Type Insights
Blood samples dominated the market with a share of 47.41% in 2023. The frequent use of blood samples by clinicians and the application of diagnostic kits for evaluating various disease conditions, organ functioning, and risk factor analysis are the factors supporting the growth of the segment. Additionally, the launch of new diagnostic devices that use blood for detection and screening is boosting market growth. For instance, Osler, a blood-testing startup, is tapping investors for funds before the big launch of its diagnostic device. The new technology will deliver results in 10 minutes, and it aims to provide cheap blood tests.
Urine samples held the second-largest market share and are expected to grow at a lucrative rate in the forecast period. Urine collection is patient-friendly as it is non-invasive and much quicker because it doesn’t require technical personnel. Research has also demonstrated that oxidative stress can be successfully evaluated through urine screening. For instance, in a research article published in July 2020, researchers from Japan proved that the presence of pteridine derivatives in urine is associated with oxidative stress and smoking. Thus, the increased testing of oxidative stress in the human body is also expected to fuel the growth of urine sample type screening in the market.
Collection Site Insights
In 2023, the hospital segment accounted for the largest revenue share at 41.0%. For the majority of the population, hospitals are the centers for primary diagnosis and treatment. The use of diagnostic kits for both in-patients and out-bound patients for health screening is one of the major factors contributing to the growth. Moreover, the presence of medical professionals and the recommendation of diagnostic tests for disease identification are fueling the growth of the market. The presence of sample collection sites, skilled professionals, and advanced diagnostic techniques in one place is anticipated to further contribute to growth.
The home segment is estimated to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing awareness regarding health and self-sampling adoption in major markets. The adoption of self-sampling is because it is user-friendly and doesn’t require specific infrastructure or trained professionals. Moreover, the COVID-19 pandemic led to the mass preference for home collections due to limited movements, and this preference will continue even in the years to come. For example, Lab Corp announced in April 2023 that it has launched a home collection service for various diagnostic and screening test offerings of the company.
Regional Insights
North America accounted for the largest share (51.0%) of the cellular health screening market in 2023. The rising awareness regarding health among individuals driving the Healthy Life Expectancy (HALE), growing healthcare expenditure, and government funding for preventative healthcare are some of the key contributing factors in this region. Furthermore, the presence of major key players, easy adoption of new technologies, and the burden of infectious and chronic diseases in the population are contributing to regional growth.
Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period. This is due to the presence of a growing population that contributes to a larger patient pool and the developing healthcare infrastructure due to increasing economies. The improved adoption of tests and health consciousness among adult individuals are the key driving factors in the Asia Pacific. Moreover, increased research on telomere for senescence and government initiatives for the prevention of diseases is supporting regional growth.
Some of the prominent players in the cellular health screening market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global cellular health screening market.
Test Type
Sample Type
Collection Site
By Region
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Test Type
1.1.1.1 Sample Type
1.1.1.1 Collection Site
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Test Type and Sample Type Snapshot
2.3 Collection Site Snapshot
2.4 Competitive Snapshot
Chapter 3 Cellular Health Screening Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rise in the adoption of telomere performance programs to lead a healthy life
3.3.1.2 Increase in importance of health-adjusted life expectancy (HALE)
3.3.1.3 Increasing government focus on preventive healthcare
3.3.1.4 Rise in geriatric population leading to growth in the need for cellular health screening
3.3.1.5 Increase in research activities
3.3.1.5 Growth in the adoption of direct-to-consumer approach for the availability of kits
3.3.1.7 Rise in burden of chronic diseases
3.3.2 Market restraint analysis
3.3.2.1 Problems associated with the transport of samples
3.3.2.2 Differences in the cost of test kits offered by different companies
3.3.3 Industry challenges
3.4 Cellular Health Screening Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE Analysis
Chapter 4 Cellular Health Screening Market - Segment Analysis, By Test Type, 2024 - 2033
4.1 Cellular Health Screening Market: Test Type Movement Analysis
4.2 Single Test Panels
4.2.1 Single test panels market estimates and forecast, 2021 - 2033
4.2.2 Telomere Tests
4.2.2.1 Telomere test market estimates and forecast, 2021 - 2033
4.2.3 Oxidative Stress Tests
4.2.3.1 Oxidative stress test market estimates and forecast, 2021 - 2033
4.2.4 Inflammation Tests
4.2.4.1 Inflammation test market estimates and forecast, 2021 - 2033
4.2.5 Heavy Metals Tests
4.2.5.1 Heavy metals test market estimates and forecast, 2021 - 2033
4.3 Multi-test Panels
4.3.1 Multi-test panels market estimates and forecast, 2021 - 2033
Chapter 5 Cellular Health Screening Market - Segment Analysis, By Sample Type, 2024 - 2033
5.1 Cellular Health Screening Market: Sample Type Movement Analysis
5.2 Blood
5.2.1 Blood market estimates and forecast, 2021 - 2033
5.3 Saliva
5.3.1 Saliva market estimates and forecast, 2021 - 2033
5.4 Serum
5.4.1 Serum market estimates and forecast, 2021 - 2033
5.5 Urine
5.5.1 Urine market estimates and forecast, 2021 - 2033
Chapter 6 Cellular Health Screening Market - Segment Analysis, By Collection Site, 2024 - 2033
6.1 Cellular Health Screening Market: Collection Site Movement Analysis
6.2 Home
6.2.1 Home market estimates and forecast, 2021 - 2033
6.3 Office
6.3.1 Office market estimates and forecast, 2021 - 2033
6.4 Hospital
6.4.1 Hospital market estimates and forecast, 2021 - 2033
6.5 Diagnostic Labs
6.5.1 Diagnostic labs market estimates and forecast, 2021 - 2033
Chapter 7 Cellular Health Screening Market - Segment Analysis, By Region, 2024 - 2033
7.1 Regional Market Snapshot
7.1.1 North America
7.1.1.1 North America cellular health screening market estimates and forecast, 2021-2033
7.1.1.2 U.S.
7.1.1.2.1 U.S. cellular health screening market estimates and forecast, 2021 - 2033
7.1.1.2.2 Key country dynamics
7.1.1.2.3 Disease prevalence
7.1.1.2.4 Regulatory framework
7.1.1.2.5 Competitive scenario
7.1.1.3 Canada
7.1.1.3.1 Canada cellular health screening market estimates and forecast, 2021 - 2033
7.1.1.3.2 Key country dynamics
7.1.1.3.3 Disease prevalence
7.1.1.3.4 Regulatory framework
7.1.1.3.5 Competitive scenario
7.1.2 Europe
7.1.2.1 Europe cellular health screening market estimates and forecast, 2021-2033
7.1.2.2 UK
7.1.2.2.1 UK cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.2.2 Key country dynamics
7.1.2.2.3 Disease prevalence
7.1.2.2.4 Regulatory framework
7.1.2.2.5 Competitive scenario
7.1.2.3 Germany
7.1.2.3.1 Germany cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.3.2 Key country dynamics
7.1.2.3.3 Disease prevalence
7.1.2.3.4 Regulatory framework
7.1.2.3.5 Competitive scenario
7.1.2.4 France
7.1.2.4.1 France cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.4.2 Key country dynamics
7.1.2.4.3 Disease prevalence
7.1.2.4.4 Regulatory framework
7.1.2.4.5 Competitive scenario
7.1.2.5 Italy
7.1.2.5.1 Italy cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.5.2 Key country dynamics
7.1.2.5.3 Disease prevalence
7.1.2.5.4 Regulatory framework
7.1.2.5.5 Competitive scenario
7.1.2.6 Spain
7.1.2.6.1 Spain cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.6.2 Key country dynamics
7.1.2.6.3 Disease prevalence
7.1.2.6.4 Regulatory framework
7.1.2.6.5 Competitive scenario
7.1.2.7 Denmark
7.1.2.7.1 Denmark cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.7.2 Key country dynamics
7.1.2.7.3 Disease prevalence
7.1.2.7.4 Regulatory framework
7.1.2.7.5 Competitive scenario
7.1.2.8 Sweden
7.1.2.8.1 Sweden cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.8.2 Key country dynamics
7.1.2.8.3 Disease prevalence
7.1.2.8.4 Regulatory framework
7.1.2.8.5 Competitive scenario
7.1.2.9 Norway
7.1.2.9.1 Norway cellular health screening market estimates and forecast, 2021 - 2033
7.1.2.9.2 Key country dynamics
7.1.2.9.3 Disease prevalence
7.1.2.9.4 Regulatory framework
7.1.2.9.5 Competitive scenario
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific cellular health screening market estimates and forecast, 2021-2033
7.1.3.2 Japan
7.1.3.2.1 Japan cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.2.2 Key country dynamics
7.1.3.2.3 Disease prevalence
7.1.3.2.4 Regulatory framework
7.1.3.2.5 Competitive scenario
7.1.3.3 China
7.1.3.3.1 China cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.3.2 Key country dynamics
7.1.3.3.3 Disease prevalence
7.1.3.3.4 Regulatory framework
7.1.3.3.5 Competitive scenario
7.1.3.4 India
7.1.3.4.1 India cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.4.2 Key country dynamics
7.1.3.4.3 Disease prevalence
7.1.3.4.4 Regulatory framework
7.1.3.4.5 Competitive scenario
7.1.3.5 South Korea
7.1.3.5.1 South Korea cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.5.2 Key country dynamics
7.1.3.5.3 Disease prevalence
7.1.3.5.4 Regulatory framework
7.1.3.5.5 Competitive scenario
7.1.3.6 Australia
7.1.3.6.1 Australia cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.6.2 Key country dynamics
7.1.3.6.3 Disease prevalence
7.1.3.6.4 Regulatory framework
7.1.3.6.5 Competitive scenario
7.1.3.7 Thailand
7.1.3.7.1 Thailand cellular health screening market estimates and forecast, 2021 - 2033
7.1.3.7.2 Key country dynamics
7.1.3.7.3 Disease prevalence
7.1.3.7.4 Regulatory framework
7.1.3.7.5 Competitive scenario
7.1.4 Latin America
7.1.4.1 Latin America cellular health screening market estimates and forecast, 2021-2033
7.1.4.2 Brazil
7.1.4.2.1 Brazil cellular health screening market estimates and forecast, 2021 - 2033
7.1.4.2.2 Key country dynamics
7.1.4.2.3 Disease prevalence
7.1.4.2.4 Regulatory framework
7.1.4.2.5 Competitive scenario
7.1.4.3 Mexico
7.1.4.3.1 Mexico cellular health screening market estimates and forecast, 2021 - 2033
7.1.4.3.2 Key country dynamics
7.1.4.3.3 Disease prevalence
7.1.4.3.4 Regulatory framework
7.1.4.3.5 Competitive scenario
7.1.4.4 Argentina
7.1.4.4.1 Argentina cellular health screening market estimates and forecast, 2021 - 2033
7.1.4.4.2 Key country dynamics
7.1.4.4.3 Disease prevalence
7.1.4.4.4 Regulatory framework
7.1.4.4.5 Competitive scenario
7.1.5 MEA
7.1.5.1 MEA cellular health screening market estimates and forecast, 2021-2033
7.1.5.2 South Africa
7.1.5.2.1 South Africa cellular health screening market estimates and forecast, 2021 - 2033
7.1.5.2.2 Key country dynamics
7.1.5.2.3 Disease prevalence
7.1.5.2.4 Regulatory framework
7.1.5.2.5 Competitive scenario
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia cellular health screening market estimates and forecast, 2021 - 2033
7.1.5.3.2 Key country dynamics
7.1.5.3.3 Disease prevalence
7.1.5.3.4 Regulatory framework
7.1.5.3.5 Competitive scenario
7.1.5.4 UAE
7.1.5.4.1 UAE cellular health screening market estimates and forecast, 2021 - 2033
7.1.5.4.2 Key country dynamics
7.1.5.4.3 Disease prevalence
7.1.5.4.4 Regulatory framework
7.1.5.4.5 Competitive scenario
7.1.5.5 Kuwait
7.1.5.5.1 Kuwait cellular health screening market estimates and forecast, 2021 - 2033
7.1.5.5.2 Key country dynamics
7.1.5.5.3 Disease prevalence
7.1.5.5.4 Regulatory framework
7.1.5.5.5 Competitive scenario
Chapter 8 COMPETITIVE LANDSCAPE
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Life Length
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 SpectraCell Laboratories, Inc.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 RepeatDx
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 Cell Science Systems
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product benchmarking
8.4.4.4 Strategic initiatives
8.4.5 Quest Diagnostics Incorporated
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic initiatives
8.4.6 Laboratory Corporation of America Holdings
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 OPKO Health, Inc.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Genova Diagnostics (GDX)
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Immundiagnostik AG
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 DNA Labs India
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers